Stonepine Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Stonepine Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,000	Closed	-$1.13M	–	68
2025 Q2	$1.13M	Buy	100,000 +78,450	+364%	+$959K	1.11%	24
2025 Q1	$249K	Buy	+21,550	New	+$220K	0.24%	46
2021 Q4	–	Sell	-200,000	Closed	-$3.49M	–	30
2021 Q3	$3.49M	Hold	200,000	–	–	1.59%	15
2021 Q2	$4.79M	Sell	200,000 -222,310	-53%	-$5.82M	2.51%	14
2021 Q1	$10.8M	Buy	+422,310	New	+$11.1M	5.86%	5
2019 Q4	–	Sell	-33,033	Closed	-$383K	–	27
2019 Q3	$383K	Buy	+33,033	New	+$534K	0.37%	21
2018 Q4	–	Sell	-138,100	Closed	-$3.05M	–	25
2018 Q3	$3.05M	Buy	+138,100	New	+$1.87M	1.79%	17

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stonepine Capital Management's KALV Position: Q3 2025 in Review

Stonepine Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 100,000 shares — an estimated $1.13M sold.

Stonepine Capital Management first reported a position in KALV in Q3 2018 and held it in 7 quarters. The position peaked at $10.8M in Q1 2021. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

Stonepine Capital Management reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Stonepine Capital Management sold 100,000 KalVista Pharmaceuticals shares in Q3 2025, an estimated $1.13M.
Stonepine Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 7 quarters.
Stonepine Capital Management's KalVista Pharmaceuticals position peaked at $10.8M in Q1 2021.
145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.